Detalhe da pesquisa
1.
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study.
J Thromb Thrombolysis
; 54(3): 373-381, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36036856
2.
Influence of Lipid Excipients on Platelet Function and the Pharmacodynamic Effects of Aspirin.
J Cardiovasc Pharmacol
; 78(2): 297-301, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33657049
3.
Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation.
J Thromb Thrombolysis
; 49(3): 337-343, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32080811
4.
Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study.
J Thromb Thrombolysis
; 48(4): 554-562, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31420787
5.
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial.
Eur Heart J
; 39(46): 4112-4121, 2018 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30203006
6.
First Safety and Performance Evaluation of T45K, a Self-Assembling Peptide Barrier Hemostatic Device, After Skin Lesion Excision.
Dermatol Surg
; 44(7): 939-948, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29381543
7.
Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
Circulation
; 134(10): 723-33, 2016 Sep 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27482008
8.
Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial.
Circulation
; 133(3): 248-55, 2016 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-26762525
9.
Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.
Am Heart J
; 188: 147-155, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28577670
10.
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
Eur Heart J
; 37(14): 1122-30, 2016 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26400827
11.
Effect of platelet inhibition with cangrelor during PCI on ischemic events.
N Engl J Med
; 368(14): 1303-13, 2013 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-23473369
12.
Bivalirudin started during emergency transport for primary PCI.
N Engl J Med
; 369(23): 2207-17, 2013 Dec 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-24171490
13.
Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database.
Catheter Cardiovasc Interv
; 87(3): 363-73, 2016 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26011467
14.
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials.
J Thromb Thrombolysis
; 40(3): 317-22, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26024789
15.
Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis.
J Am Coll Cardiol
; 83(17): 1627-1636, 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38658101
16.
Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study.
J Cardiovasc Pharmacol
; 62(5): 466-78, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23921301
17.
Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery.
Heart Surg Forum
; 16(2): E60-9, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23625478
18.
Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials.
J Thromb Thrombolysis
; 34(1): 44-55, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22569899
19.
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.
JAMA
; 307(3): 265-74, 2012 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-22253393
20.
Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective.
Am J Cardiovasc Drugs
; 22(1): 93-104, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34331235